Evaluation of Serum Cytokeratines, Thymidine Kinase, and Growth Factors as Cancer Biomarkers in Colorectal Cancer
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články
PubMed
38925804
DOI
10.21873/anticanres.17124
PII: 44/7/3105
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer biomarker, cytokeratines, diagnosis, prognosis, thymidine kinase,
- MeSH
- antigen CA-19-9 * krev MeSH
- antigeny nádorové krev MeSH
- dospělí MeSH
- insulinu podobný růstový faktor I metabolismus MeSH
- karcinoembryonální antigen * krev MeSH
- keratin-19 krev MeSH
- keratiny krev MeSH
- kolorektální nádory * krev diagnóza patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery * krev MeSH
- peptidy MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- ROC křivka MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- thymidinkináza * krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antigen CA-19-9 * MeSH
- antigen CYFRA21.1 MeSH Prohlížeč
- antigeny nádorové MeSH
- insulinu podobný růstový faktor I MeSH
- karcinoembryonální antigen * MeSH
- keratin-19 MeSH
- keratiny MeSH
- nádorové biomarkery * MeSH
- peptidy MeSH
- thymidinkináza * MeSH
- tissue polypeptide specific antigen MeSH Prohlížeč
BACKGROUND/AIM: Classical serum cancer biomarkers, such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), remain important tools in colorectal cancer (CRC) management for disease follow up. However, their sensitivity and specificity are low for diagnostic and prognostic evaluation. The aim of this study was to evaluate the potential of biomarkers reflecting biological activity of tumors - tissue polypeptide specific antigen (TPS), cytokeratin fragment 19 (CYFRA 21-1), thymidine kinase (TK), insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGF-BP3) - together with the CEA and CA 19-9 in CRC diagnosis and prognosis. PATIENTS AND METHODS: This is a retrospective study including 148 CRC patients and 68 age-matched healthy subjects. Serum biomarkers were measured in pre-operative serum samples using immunoanalytical methods. The end-point for the diagnostic evaluation was the area under the receiving operating characteristic curve (AUC ROC) of the biomarkers. The end-point for the prognostic evaluation was overall survival. RESULTS: Serum levels of CEA, CA 19-9, TPS, and TK were significantly increased in CRC early-stage patients compared with healthy controls. Each of the studied biomarkers had AUC between 0.6 and 0.7. Analysis of survival demonstrated that the patients with CEA, CA 19-9, cytokeratin, and TK above optimal cut offs had significantly shorter survival. A multivariate analysis performed on all the study biomarkers resulted in the selection of CYFRA 21-1 as the best performing biomarker with hazard ratio 10.413. CONCLUSION: The combination of cytokeratins and thymidine kinase with classical cancer biomarkers enables the prediction of tumor aggressiveness and long-term prognosis.
Citace poskytuje Crossref.org